Historical record - last NADAC effective date: 10/19/2022
Product Information
QC NIGHT SEVERE COLD-COUGH PKT is a generic product labeled by Chain Drug Marketing Association, priced at $0.4817 per EA under NDC 63868029106. Its NADAC has been published 10 times since Oct 19, 2022.
Strength
650; 25; 10 mg/1; mg/1; mg/1
Manufacturer
Chain Drug Marketing AssociationNDC
63868029106
Classification
Generic
Dosage Form
POWDER, FOR SOLUTION
Route
ORAL
Effective Date
10/19/2022
Approval Type
OTC MONOGRAPH DRUG
FDA Application
M012On Market Since
7/16/2018
Pharmacological Classes
Price Statistics
The NADAC for QC NIGHT SEVERE COLD-COUGH PKT has been published 10 times since Oct 19, 2022, and over the history we have for it it has held within roughly two percent of its current level. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.4817 per EA |
|---|---|
| All-time high | $0.4817 (Dec 21, 2022) |
| All-time low | $0.4817 (Oct 19, 2022) |
| Median price | $0.4817 |
| Average price | $0.4817 |
| Largest weekly change | 0.0% (Oct 26, 2022) |
| Weeks tracked | 10 |
| Tracking since | Oct 19, 2022 |
1W
N/A
1M
N/A
3M
N/A
6M
N/A
1Y
N/A
3Y
N/A
5Y
N/A
All
0.0%
Last surveyed Dec 21, 2022 — this NDC no longer appears in the current weekly NADAC file.
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the ACETAMINOPHEN, DIPHENHYDRAMINE, PHENYLEPHRINE market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Chain Drug Marketing Association manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
ACETAMINOPHEN, DIPHENHYDRAMINE, PHENYLEPHRINE market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Histamine-1 Receptor Antagonist class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of QC NIGHT SEVERE COLD-COUGH PKT?
The current National Average Drug Acquisition Cost (NADAC) for QC NIGHT SEVERE COLD-COUGH PKT, manufactured by Chain Drug Marketing Association, is $0.4817 per EA (NDC 63868029106), effective Dec 21, 2022.
How has the price of QC NIGHT SEVERE COLD-COUGH PKT changed over time?
Over the history we have for it, the NADAC for QC NIGHT SEVERE COLD-COUGH PKT has held within roughly two percent of its current level. It has been tracked across 10 weekly CMS publications since Oct 19, 2022.
What are the highest and lowest recorded NADAC prices for QC NIGHT SEVERE COLD-COUGH PKT?
Since Oct 19, 2022, the NADAC for QC NIGHT SEVERE COLD-COUGH PKT has ranged from a low of $0.4817 (Oct 19, 2022) to a high of $0.4817 (Dec 21, 2022), with a median of $0.4817 per EA.
Are there cheaper alternatives to QC NIGHT SEVERE COLD-COUGH PKT?
No other NADAC-published product currently shares the active ingredient and strength of QC NIGHT SEVERE COLD-COUGH PKT in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures QC NIGHT SEVERE COLD-COUGH PKT?
QC NIGHT SEVERE COLD-COUGH PKT (NDC 63868029106) is labeled by Chain Drug Marketing Association, and CMS classifies it as a generic product.